Reply to L. C. Mendez et al and M. A. Kollmeier et al.
作者信息
Jackson William C, Hartman Holly E, Dess Robert T, Spratt Daniel E
机构信息
William C. Jackson, MD; Holly E. Hartman, MS; Robert T. Dess, MD; and Daniel E. Spratt, MD, University of Michigan, Ann Arbor, MI.
出版信息
J Clin Oncol. 2020 Nov 10;38(32):3823-3824. doi: 10.1200/JCO.20.02422. Epub 2020 Sep 30.
Abstract
摘要
相似文献
1
Reply to L. C. Mendez et al and M. A. Kollmeier et al.对L. C. 门德斯等人及M. A. 科尔迈尔等人的回复
J Clin Oncol. 2020 Nov 10;38(32):3823-3824. doi: 10.1200/JCO.20.02422. Epub 2020 Sep 30.
2
Brachytherapy and Androgen-Deprivation Therapy in Patients With Intermediate- and High-Risk Prostate Cancer: Not Necessarily an Either/Or Decision.中高危前列腺癌患者的近距离放射治疗与雄激素剥夺治疗：不一定是二选一的决定。
J Clin Oncol. 2020 Nov 10;38(32):3820-3821. doi: 10.1200/JCO.20.01566. Epub 2020 Sep 30.
3
Role of Androgen-Deprivation Therapy Remains Uncertain for Intermediate-Risk Patients When Using Dose-Escalated Radiotherapy.在使用剂量递增放疗时，雄激素剥夺疗法对中危患者的作用仍不确定。
J Clin Oncol. 2020 Nov 10;38(32):3821-3822. doi: 10.1200/JCO.20.02105. Epub 2020 Sep 30.
4
Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials.局部前列腺癌外照射放疗中添加雄激素剥夺治疗或近距离放疗增敏：一项随机试验的网络荟萃分析。
J Clin Oncol. 2020 Sep 10;38(26):3024-3031. doi: 10.1200/JCO.19.03217. Epub 2020 May 12.
5
Do Older Patients With Metastatic Hormone-Sensitive Prostate Cancer Benefit From Triplet or Doublet Therapy? A Network Meta-Analysis.老年转移性激素敏感性前列腺癌患者从三联或双联疗法中获益吗？一项网状Meta分析。
Clin Genitourin Cancer. 2025 May 30:102380. doi: 10.1016/j.clgc.2025.102380.
6
A systematic review of randomized trials in localized prostate cancer.一项关于局限性前列腺癌随机试验的系统评价。
Can J Urol. 2004 Feb;11(1):2110-7.
7
Reply to Yongfeng Lao, Yanan Wang, and Zhilong Dong's Letter to the Editor re: Amar U. Kishan, Xiaoyan Wang, Yilun Sun, et al. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium. Eur Urol. 2022;82:106-114.回复劳永丰、王亚楠和董志龙致编辑的信，信的内容是关于阿马尔·U·基尚、王小燕、孙逸伦等人的研究：《高剂量放疗或雄激素剥夺疗法（HEAT）作为局限性前列腺癌治疗强化手段：来自MARCAP联盟的个体患者数据网络荟萃分析》。《欧洲泌尿外科杂志》。2022年；82卷：106 - 114页。
Eur Urol. 2022 Sep;82(3):e82-e83. doi: 10.1016/j.eururo.2022.05.033. Epub 2022 Jun 7.
8
Re: Bo Dai, Sheng Zhang, Fan-Ning Wan, et al. Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer : A Phase 2 Randomized Controlled Trial. Eur Urol Oncol 2022;5:519-25.
Eur Urol Oncol. 2023 Aug;6(4):451. doi: 10.1016/j.euo.2023.01.006. Epub 2023 Jan 25.
9
Considerations Regarding a Network Meta-analysis of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer-Reply.关于转移性去势敏感性前列腺癌全身治疗网络Meta分析的思考——回复
JAMA Oncol. 2021 Jul 1;7(7):1069-1070. doi: 10.1001/jamaoncol.2021.0966.
10
Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.系统治疗对有内脏转移的前列腺癌患者的疗效：系统评价、荟萃分析和网络荟萃分析。
J Urol. 2023 Sep;210(3):416-429. doi: 10.1097/JU.0000000000003594. Epub 2023 Jun 20.
本文引用的文献
1
Role of Androgen-Deprivation Therapy Remains Uncertain for Intermediate-Risk Patients When Using Dose-Escalated Radiotherapy.在使用剂量递增放疗时，雄激素剥夺疗法对中危患者的作用仍不确定。
J Clin Oncol. 2020 Nov 10;38(32):3821-3822. doi: 10.1200/JCO.20.02105. Epub 2020 Sep 30.
2
Brachytherapy and Androgen-Deprivation Therapy in Patients With Intermediate- and High-Risk Prostate Cancer: Not Necessarily an Either/Or Decision.中高危前列腺癌患者的近距离放射治疗与雄激素剥夺治疗：不一定是二选一的决定。
J Clin Oncol. 2020 Nov 10;38(32):3820-3821. doi: 10.1200/JCO.20.01566. Epub 2020 Sep 30.
3
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.无事件生存，一种基于前列腺特异性抗原的复合终点，不能替代局部前列腺癌男性接受放疗后的总生存。
J Clin Oncol. 2020 Sep 10;38(26):3032-3041. doi: 10.1200/JCO.19.03114. Epub 2020 Jun 18.
4
Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials.局部前列腺癌外照射放疗中添加雄激素剥夺治疗或近距离放疗增敏：一项随机试验的网络荟萃分析。
J Clin Oncol. 2020 Sep 10;38(26):3024-3031. doi: 10.1200/JCO.19.03217. Epub 2020 May 12.
5
Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial.局部晚期前列腺癌患者中增加放疗剂量或延长雄激素抑制以预防远处转移：来自 TROG 03.04 RADAR 试验的 10 年数据。
Int J Radiat Oncol Biol Phys. 2020 Mar 15;106(4):693-702. doi: 10.1016/j.ijrobp.2019.11.415.
6
Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.无转移生存期是局限性前列腺癌总生存期的有力替代指标。
J Clin Oncol. 2017 Sep 20;35(27):3097-3104. doi: 10.1200/JCO.2017.73.9987. Epub 2017 Aug 10.
7
Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.局部晚期前列腺癌雄激素剥夺治疗的持续时间：NRG肿瘤学RTOG 9202的长期更新
Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):296-303. doi: 10.1016/j.ijrobp.2017.02.004. Epub 2017 Feb 12.
8
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.雄激素抑制联合选择性淋巴结及剂量递增放射治疗（ASCENDE-RT试验）：一项针对高风险和中风险前列腺癌的随机试验的生存终点分析，该试验比较了低剂量率近距离放疗增敏与剂量递增外照射增敏。
Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):275-285. doi: 10.1016/j.ijrobp.2016.11.026. Epub 2016 Nov 24.
9
Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991.短程雄激素抑制联合放疗治疗中高危局限性前列腺癌：EORTC 试验 22991 结果。
J Clin Oncol. 2016 May 20;34(15):1748-56. doi: 10.1200/JCO.2015.64.8055. Epub 2016 Mar 14.
10
High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.高剂量放疗联合短期或长期雄激素剥夺治疗局限性前列腺癌（DART01/05 GICOR）：一项随机、对照、3 期临床试验。
Lancet Oncol. 2015 Mar;16(3):320-7. doi: 10.1016/S1470-2045(15)70045-8. Epub 2015 Feb 19.
Zotero 插件